A $1,000 investment in XRP on September 18, 2025, when the first US XRP spot ETF (XRPR) launched, is now worth $428.60, down 57%. XRP's price dropped from $3.08 to $1.32 over 12 months, though it has rebounded over 33% in the past 35 days. Despite the price decline, XRP benefits from strong fundamentals including $46.24 million in assets under management for XRPR, multiple new US spot ETFs with $1.7 billion net inflows, and Ripple Labs' efforts to boost institutional adoption. Regulatory clarity in the US also supports XRP's outlook, suggesting potential value growth if the recent uptrend continues.
The story covers XRP's investment value change since the first US XRP spot ETF launch. For readers following US stocks on Pluang, here is the market snapshot as of Sep 18, 2026 20:34 WIB: out of 150 priced US stocks, 46 rose and 101 fell. Notable movers include Kraft Heinz Co (KHC) at USD 24.28 with 84% sell orders, Gold Fields Limited (GFI) at USD 42.54 with 53% buy orders, and Walt Disney Co (DIS) at USD 103.50 with 79% buy orders.
Peter Thiel's investment fund, which held no stocks for two consecutive quarters, has made a significant comeback with $419 million in new investments. Notably, 72% of this capital has been allocated to the energy and power sectors, signaling a strat...
McCormick & Company reported strong Q2 results with a 30.1% rise in adjusted operating income and a 16.7% increase in sales. The company, known for its long history of dividend increases, trades at about 16 times projected 2026 earnings and offers a ...
Grayscale Bitcoin Mini Trust (BTC) rose about 5.8% following Bitcoin's rebound above $80,000, reflecting renewed investor interest after the U.S. Senate failed to advance the CLARITY Act. The trust offers exposure to Bitcoin without direct ownership ...
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
